velocity (MNCV) kept increasing with time in the nondiabetic control rats and reached a plateau at 16 weeks, initially no such increase was noted in diabetic rats on aminoguanidine. However, after 2 months of treatment a dose-dependent progressive increase in MNCV was noted, which, at the dose of 50 mg/kg body weight, reached almost normal levels at 16 weeks. Morphometric analysis of the sciatic nerve revealed no significant differences between diabetic animals receiving aminoguanidine and controls. The improvement in MNCV did not appear to relate to glycemic status or amelioration in body weight, both of which were unchanged at 16 weeks compared to what they were at study onset (10) , thereby preventing formation of pyrrole-AGEs like pyrraline (11, 12) . Pyrroles have been proposed as a basis for hexane-induced neuropathy in experimental animals and humans (12) . Such pyrroles could form from 3-deoxyglucosone as a metabolite of the fructose-3-phosphate pathway that has been found to be aldose reductase-dependent in the lens (13 (2) . Moreover, they showed that chronic administration of l-NAME to normal rats impaired NCV and suppressed Na+,K+-ATPase. Thus 
